QIAGEN powered by

Hereditary NGS Clinical Software Series

Building a next-gen software workflow for germline testing

A two-part event: October 13 and November 10

Agenda

This is a two-part virtual event with two different sessions in a European time zone (CEST) and North American time zone (EST).

Part 1: Thursday, October 13, 2022

An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.

10:00 – 10:30 am (CEST) | 1:00 – 1:30 pm (EST)

Simplify your secondary analysis from FASTQ to VCF in 5 steps 

  • Variant calling, filtering and visualization: Structural variants, indels, point mutations
  • Quality control reports
  • Get started quickly with configurable pre-made workflows

10:30 – 11:00 am (CEST) | 1:30 – 2:00 pm (EST)

Solve every hereditary disorder case for all types of genetic mutations

  • Why lab’s need high-quality, deeply curated knowledge to skip the diagnostic odyssey 

  • How you can interpret complex germlines cases and increase your diagnostic yield with QCI Interpret

  • How QCI Interpret displays and interprets copy number variants

11:00 – 11:30 am (CEST) | 2:00 – 2:30 pm (EST)

Going beyond the exome

  • Addressing current challenges in germline and exome analytics
  • Solving complex germline cases with the most comprehensive content from QIAGEN Digital Insights
Speakers
Tim Bonnert, Ph.D. Director, Field Application Scientists (EMEA) QIAGEN Digital Insights
Tim Bonnert, Ph.D. Director, Field Application Scientists
QIAGEN Digital Insights
Ruth Burton, Ph.D. Clinical Field Application Scientist
QIAGEN Digital Insights
Michael Furness Professional Customer Solutions Manager
QIAGEN Digital Insights
Malaina Gaddis, Ph.D. Clinical Field Application Scientist
QIAGEN Digital Insights
Neha Jalan, Ph.D. Professional Services Solution Manager
QIAGEN Digital Insights
Georgios Stamoulis, Ph.D. Director, Global Product Manager Hereditary
QIAGEN Digital Insights
Part 2: Thursday, November 10, 2022

An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing.

Attendees will gain:

  • Insight into how leading laboratories address bottlenecks in their NGS data pipelines
  • Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants
  • An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation